What is Myocardial Late Gadolinium Enhancement (LGE)?
Myocardial late gadolinium enhancement (LGE) is a cardiac MRI technique that visualizes areas of myocardial scar, fibrosis, or necrosis by detecting the differential accumulation of gadolinium-based contrast agents in damaged versus normal heart tissue, appearing as bright (hyperenhanced) regions approximately 10-15 minutes after contrast injection. 1
Technical Mechanism
LGE works through a straightforward physiological principle:
- Gadolinium-based contrast agents distribute into the extracellular space following intravenous injection
- In damaged myocardium (whether from infarction, inflammation, or fibrosis), there is expansion of the extracellular matrix that allows greater gadolinium accumulation
- After 10-15 minutes, contrast washes out of normal myocardium but remains concentrated in damaged areas, creating maximum differential enhancement 1
- Inversion-recovery pulse sequences null the signal from normal myocardium (appears black), while scarred tissue with shorter T1 values appears bright white 2, 1
Spatial Resolution and Accuracy
LGE provides near-histological precision with approximately 1×1 mm in-plane spatial resolution, allowing visualization of scar with exceptional detail 1. This technique has been extensively validated against histopathology and is now considered the reference standard for non-invasive imaging of myocardial scar and focal fibrosis in both ischemic and non-ischemic cardiomyopathies 1.
Clinical Applications
Ischemic Heart Disease
- Predicts myocardial viability: Segments with <25% transmural LGE have high probability of functional recovery after revascularization, while >75% transmurality indicates non-viable tissue 1
- Quantifies infarct size and transmural extent of scarring
- The peri-infarct grey zone (mix of viable myocytes and collagen) predicts ventricular arrhythmias and appropriate ICD discharges 1
Non-Ischemic Cardiomyopathies
- Detects myocardial necrosis and fibrosis in inflammatory conditions (myocarditis) 2
- Characterizes hypertrophic cardiomyopathy, dilated cardiomyopathy, and infiltrative diseases
- Helps distinguish ischemic from non-ischemic cardiomyopathy based on enhancement patterns 3
Prognostic Value
- LGE volume and transmurality are independent predictors of mortality, with incremental value beyond ejection fraction 1
- LGE extent >23% predicts adverse events 1
- Predicts LV reverse remodeling after cardiac resynchronization therapy 1
Important Caveats
Limitations to Recognize:
- LGE shows extracellular matrix expansion regardless of cause (collagen, water, amyloid infiltration), so it may overestimate scar extent in the presence of myocardial edema, particularly in acute myocardial infarction 1
- Intermediate transmurality (25-75%) has limited predictive accuracy: sensitivity 91% but specificity only 51% for predicting regional functional recovery 1
- Requires gadolinium-based contrast injection, which carries risks of allergic reactions/anaphylaxis and is contraindicated in pregnancy (though second/third trimester use may be safer) 1
Technical Considerations:
- Standard protocols use phase-sensitive inversion recovery sequences with images in multiple planes (short-axis stack plus 2-, 3-, and 4-chamber long-axis views) 1
- Interpretation should ideally be quantitative rather than purely visual 1
- Newer high-resolution 3D whole-heart LGE techniques (up to 1.3×1.3×1.3 mm³) can detect smaller scars and atrial fibrosis, though scan times extend to ~10 minutes 4
Practical Interpretation
Normal myocardium = black (no enhancement) = viable tissue
Bright hyperenhancement = scar/fibrosis = non-viable tissue
Absence of LGE = viability 1
The transmural extent creates a spectrum: no scar (fully viable) → subendocardial scar (partially viable) → transmural scar (non-viable) 1.